397 related articles for article (PubMed ID: 34802443)
1. m
Zhang Z; Zhang C; Luo Y; Wu P; Zhang G; Zeng Q; Wang L; Yang Z; Xue L; Zheng B; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
BMC Med; 2021 Nov; 19(1):284. PubMed ID: 34802443
[TBL] [Abstract][Full Text] [Related]
2. m
Zhang Z; Zhang C; Yang Z; Zhang G; Wu P; Luo Y; Zeng Q; Wang L; Xue Q; Zhang Y; Sun N; He J
J Hematol Oncol; 2021 Nov; 14(1):190. PubMed ID: 34758859
[TBL] [Abstract][Full Text] [Related]
3. An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer.
Wang L; Wu P; Shen Z; Yu Q; Zhang Y; Ye F; Chen K; Zhao J
Int Immunopharmacol; 2023 Apr; 117():109827. PubMed ID: 36989973
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of N
Luo Y; Zhang Z; Zheng B; Wu P; Zhang G; Wang L; Zeng Q; Yang Z; Xue L; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
Cancer Sci; 2022 Dec; 113(12):4289-4299. PubMed ID: 36047973
[TBL] [Abstract][Full Text] [Related]
5. Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer.
Zhang Z; Wu P; Zhang C; Luo Y; Zhang G; Zeng Q; Wang L; Yang Z; Sun N; He J
Front Immunol; 2021; 12():745769. PubMed ID: 34867972
[TBL] [Abstract][Full Text] [Related]
6. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
8. Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer.
Wu P; Zhang Z; Yang Z; Zhang C; Luo Y; Zhang G; Wang L; Xue Q; Sun N; He J
Cancer Immunol Immunother; 2023 Mar; 72(3):617-631. PubMed ID: 36002754
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
10. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM
J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
12. An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer.
Zhang Z; Luo Y; Zhang C; Wu P; Zhang G; Zeng Q; Wang L; Xue L; Yang Z; Zeng H; Zheng B; Tan F; Xue Q; Gao S; Sun N; He J
Cancer Cell Int; 2021 Dec; 21(1):691. PubMed ID: 34930244
[TBL] [Abstract][Full Text] [Related]
13. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
[No Abstract] [Full Text] [Related]
14. Unravelling the biology of SCLC: implications for therapy.
Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
[TBL] [Abstract][Full Text] [Related]
15. A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy.
Bi N; Cao J; Song Y; Shen J; Liu W; Fan J; He J; Shi Y; Zhang X; Lu N; Zhan Q; Wang L
PLoS One; 2014; 9(3):e91388. PubMed ID: 24637927
[TBL] [Abstract][Full Text] [Related]
16. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
17. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Shirasawa M; Yoshida T; Shiraishi K; Takigami A; Takayanagi D; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
Lung Cancer; 2023 May; 179():107183. PubMed ID: 37037178
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
19. The maximum tumor growth rate predicts clinical outcomes of patients with small-cell lung cancer undergoing first-line chemotherapy plus immune-checkpoint inhibitor therapy.
Chen X; Chen X; Liu T; Zhou T; Chen G; Zhou H; Huang Y; Fang W; Yang Y; Zhou N; Chen L; Mo S; Zhang L; Zhao Y
Cancer Med; 2023 Apr; 12(7):8122-8133. PubMed ID: 36629288
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
Qi W; Zhao S; Chen J
Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
